Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 3, 2011

Teva reacts to third-quarter results, delays laquinimod

Following mixed third-quarter results, Teva Pharmaceutical has reduced its full-year forecast and has announced it will delay seeking US approval for multiple sclerosis medication laquinimod.

By Liam Stoker

Following mixed third-quarter results, Teva Pharmaceutical has reduced its full-year forecast and has announced it will delay seeking US approval for multiple sclerosis medication laquinimod.

Although group sales rose 2.2% to $4.34bn, Teva suffered from tumbling turnover in the US, falling 48% to $845m owing to emerging generic competition.

Teva has now adjusted its 2011 sales forecast to between $18.3bn and $18.6bn, down from the $18.5bn-$19bn it originally predicted.

Teva chief executive Shlomo Yanai also revealed that laquinimod will be held back, adding that the company would continue to work with the US Food and Drug Administration in order to determine the best design for an additional trial.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU